Kabeer Aziz - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Kabeer Aziz
Issuer symbol
ANTX
Transactions as of
24 Mar 2022
Net transactions value
$0
Form type
3
Filing time
24 Mar 2022, 21:24:54 UTC
Next filing
31 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANTX Series A Convertible Preferred Stock 24 Mar 2022 Common Stock 1,651,636 By Adjuvant Global Health Technology Fund, L.P. F1, F2
holding ANTX Series A Convertible Preferred Stock 24 Mar 2022 Common Stock 312,415 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
holding ANTX Series B Convertible Preferred Stock 24 Mar 2022 Common Stock 392,433 By Adjuvant Global Health Technology Fund, L.P. F1, F2
holding ANTX Series B Convertible Preferred Stock 24 Mar 2022 Common Stock 74,230 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
F2 Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is a Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F3 Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is the AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is a Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

Remarks:

Exhibit 24 - Power of Attorney